Lab21, Novacyt to Combine in $34.1M Stock-for-Stock Deal | GenomeWeb

NEW YORK (GenomeWeb) – Liquid-based cytology diagnostics firm Novacyt today announced its intention to combine with Lab21 in a stock-for-stock transaction valued at approximately €40 million ($34.1 million).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.